Matis Medical
Whole-blood Platelet Function Testing
Company Overview
Snapshot
Founded in January 2000, Matis Medical operates with 1–10 employees. The company is in the Pre-Funding stage, focusing on developing point-of-care systems for real-time, whole-blood platelet function testing. Its core technology, the Cone and Plate(let) Analyzer (CPA), was patented through Ramot, Tel Aviv University's Authority for Applied Research & Industrial Development, which granted Matis Medical exclusive worldwide commercialization rights.
Business overview
Matis Medical specializes in Health Tech & Life Sciences, developing medical devices for real-time, whole-blood platelet function testing. The company's primary product is the Cone and Plate(let) Analyzer (CPA), with its first two products being the Impact and Impact-R systems. These systems are designed for clinical and point-of-care laboratories, serving the biotechnology, laboratories, and provider segments within the healthcare and life sciences industries. The technology is intended to screen for congenital primary hemostasis abnormalities and test platelet response to various medications.
Log in to access full profile ›Company Intelligence Q&A
- What is Matis Medical's primary focus?
- Matis Medical focuses on developing point-of-care systems for real-time, whole-blood platelet function testing, primarily through its Cone and Plate(let) Analyzer (CPA) technology.
- When was Matis Medical founded?
- Matis Medical was founded in January 2000.
- What are Matis Medical's key products?
- Matis Medical's key products are the Impact and Impact-R systems, which are based on their Cone and Plate(let) Analyzer (CPA) technology.
- What is the commercial status of Matis Medical's Impact system?
- The Impact system for clinical and point-of-care laboratories is currently in development and is not yet commercially available.
- Who invented the CPA technology and how did Matis Medical acquire rights to it?
- The CPA technology was invented by Prof. David Varon and Prof. Naphtali Savion and patented through Ramot, Tel Aviv University. Ramot granted Matis Medical exclusive worldwide commercialization rights for the technology.